Physician profile
Arshad Ali
NPI 1285084079
$1,058.17
in general payments reported to CMS, 2019-2025
12 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Obesity Medicine (Internal Medicine) provider received nationally (typical 2025 total: $202).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.35 · 2020: $51.58 · 2022: $86.47 · 2023: $82.25 · 2024: $234 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $352.18 | 2022-2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $154.23 | 2022-2025 | Zepbound |
| Medtronic, INC. | $145.26 | 2025 | V-Loc 180 |
| Boston Scientific Corporation | $124.38 | 2025 | Overstitch Endoscopic Suturing System |
| Abbvie INC. | $63.57 | 2019-2024 | |
| Ethicon US, LLC | $63.26 | 2022-2023 | Enseal, Echelon Endopath, Echelon; Endopath |
| Amarin Pharma, INC. | $36.96 | 2019-2020 | |
| Pfizer INC. | $30.77 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $28.00 | 2019-2020 | |
| Akebia Therapeutics INC | $20.62 | 2019 | |
| Amgen INC. | $19.51 | 2025 | Otezla, Repatha |
| Vivus LLC | $19.43 | 2024 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.